High Growth Tech Stocks To Watch This November 2024

In This Article:

In the wake of a significant political shift in the U.S., global markets have been buoyed by optimism surrounding potential economic growth, with major indices like the S&P 500 and Russell 2000 experiencing notable gains. As investors navigate these evolving conditions, identifying high-growth tech stocks that can capitalize on favorable regulatory and tax environments becomes crucial for those seeking to align their portfolios with current market dynamics.

Top 10 High Growth Tech Companies

Name

Revenue Growth

Earnings Growth

Growth Rating

Material Group

20.45%

24.01%

★★★★★★

Yggdrazil Group

24.66%

85.53%

★★★★★★

eWeLLLtd

26.52%

27.53%

★★★★★★

Ascelia Pharma

76.15%

47.16%

★★★★★★

Medley

24.98%

30.36%

★★★★★★

Seojin SystemLtd

33.39%

49.13%

★★★★★★

Sarepta Therapeutics

23.89%

42.65%

★★★★★★

Mental Health TechnologiesLtd

27.88%

79.61%

★★★★★★

Adveritas

57.98%

144.21%

★★★★★★

UTI

114.97%

134.60%

★★★★★★

Click here to see the full list of 1278 stocks from our High Growth Tech and AI Stocks screener.

Let's uncover some gems from our specialized screener.

ABL Bio

Simply Wall St Growth Rating: ★★★★★☆

Overview: ABL Bio Inc. is a biotech research company specializing in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases, with a market cap of ?1.94 trillion.

Operations: ABL Bio Inc. generates revenue primarily from its biotechnology segment, specifically focusing on startups, with reported earnings of ?32.95 billion. The company is engaged in developing therapeutic drugs targeting immuno-oncology and neurodegenerative diseases.

ABL Bio's recent presentation at the World ADC Conference underscores its commitment to innovation, particularly in protein engineering—a critical segment in biotech. Despite current unprofitability, the company is poised for significant growth with expected revenue increases of 24.7% annually, outpacing the Korean market's 10.2%. This potential is further underscored by an anticipated earnings surge of 48.15% per year. However, challenges remain due to its volatile share price and ongoing cash flow concerns. ABL Bio’s focus on strategic R&D investments could catalyze its transition to profitability within three years, aligning with industry benchmarks for growth and offering a glimpse into its future prospects in high-growth biotechnology sectors.

KOSDAQ:A298380 Revenue and Expenses Breakdown as at Nov 2024
KOSDAQ:A298380 Revenue and Expenses Breakdown as at Nov 2024

Hemnet Group

Simply Wall St Growth Rating: ★★★★★☆

Overview: Hemnet Group AB (publ) operates a residential property platform in Sweden with a market capitalization of approximately SEK33.93 billion.